Use: Labeled indications
- Hypertension Nicardipine
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Nicardipine hydrochloride injection is a calcium channel blocker indicated for the short-term treatment of hypertension when oral therapy is not feasible. 1.1 Hypertension Nicardipine hydrochloride injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable. For prolonged control of blood pressure, transfer patients to oral medication as soon as their clinical condition permits [see Dosage and Administration (2.6)].
Contraindications
4 CONTRAINDICATIONS Do not use in patients with advanced aortic stenosis (4.1). 4.1 Advanced Aortic Stenosis Do not use nicardipine in patients with advanced aortic stenosis because of the afterload reduction effect of nicardipine. Reduction of diastolic pressure in these patients may worsen rather than improve myocardial oxygen balance.
US FDA labelDosing: Adult
Individualize dosage based upon the severity of hypertension and response of the patient during dosing (2.1). Single dose vials must be diluted before use (2.2). When substituting for oral nicardipine therapy, use the intravenous infusion rate as follows (2.3): Oral Nicardipine Dose Equivalent IV Infusion Rate 20 mg q8h 0.5 mg/hr 30 mg q8h 1.2 mg/hr 40 mg q8h 2.2 mg/hr In a drug-free patient, initiate therapy at 5 mg/hr.
Increase the infusion rate by 2.5 mg/hr to a maximum of 15 mg/hr until desired blood pressure reduction is achieved. For a gradual blood pressure reduction the rate can be increased every 15 minutes, for a rapid reduction, every 5 minutes (2.4). If hypotension or tachycardia ensues, discontinue the infusion. After stabilized, patient can be restarted at low doses such as 3 to 5 mg/hr (2.5).
2.1 General Information
2.1 General Information Individualize dosing based on the severity of hypertension and the response of the patient during dosing. Monitor blood pressure and heart rate both during and after the infusion to avoid tachycardia or too rapid or excessive reduction in either systolic or diastolic blood pressure. Administer Nicardipine Hydrochloride by slow continuous infusion by a central line or through a large peripheral vein.
Change the infusion site every 12 hours if administered via peripheral vein [see Intravenous Infusion Site (5.7)].
2.2 Inspection and Preparation
2.2 Inspection and Preparation Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use the solution if particulate matter, precipitate, or crystallization is present, or if the container appears damaged. Single Dose Vials Dilution Single dose vials must be diluted before infusion.
Each vial (25 mg) must be diluted with 240 mL of compatible intravenous fluid (see below), resulting in 250 mL of solution at a concentration of 0.1 mg/mL. Compatability Nicardipine hydrochloride injection has been found compatible and stable in polyvinyl chloride containers for 24 hours at controlled room temperature with: Dextrose (5%) Injection, USP Dextrose (5%) and Sodium Chloride (0.45%) Injection, USP Dextrose (5%) and Sodium Chloride (0.9%) Injection, USP Dextrose (5%) with 40 mEq Potassium, USP Sodium Chloride (0.45%) Injection, USP Sodium Chloride (0.9%) Injection, USP Nicardipine hydrochloride is not compatible with Sodium Bicarbonate (5%) Injection, USP or Lactated Ringer’s Injection, USP.
2.3 Dosage
2.3 Dosage as a Substitute for Oral Nicardipine Therapy The intravenous infusion rate required to produce an average plasma concentration equivalent to a given oral dose at steady state is shown in the following table: Oral Nicardipine Dose Equivalent Intravenous Infusion Rate 20 mg q8h 0.5 mg/hr 30 mg q8h 1.2 mg/hr 40 mg q8h 2.2 mg/hr
2.4 Dosage for Initiation of Therapy in a Drug-Free Patient
2.4 Dosage for Initiation of Therapy in a Drug-Free Patient The time course of blood pressure decrease is dependent on the initial rate of infusion and the frequency of dosage adjustment. Nicardipine hydrochloride injection is administered by slow continuous infusion at a concentration of 0.1 mg/mL. With constant infusion, blood pressure begins to fall within minutes.
It reaches about 50% of its ultimate decrease in about 45 minutes. When treating acute hypertensive episodes in patients with chronic hypertension, discontinuation of infusion is followed by a 50% offset of action in 30 minutes ± 7 minutes but plasma levels of drug and gradually decreasing antihypertensive effects exist for many hours.
Titration For a gradual reduction in blood pressure, initiate therapy at a rate of 5 mg/hr. If desired blood pressure reduction is not achieved at this dose, increase the infusion rate by 2.5 mg/hr every 15 minutes up to a maximum of 15 mg/hr, until desired blood pressure reduction is achieved. For more rapid blood pressure reduction, titrate every 5 minutes.
Maintenance Adjust the rate of infusion as needed to maintain desired response.
2.5 Conditions Requiring Infusion Adjustment Hypotension or Tachycardia
2.5 Conditions Requiring Infusion Adjustment Hypotension or Tachycardia: In case of hypotension or tachycardia, discontinue infusion. When blood pressure and heart rate stabilize, restart infusion at low doses such as 30 mL/hr to 50 mL/hr (3 mg/hr to 5 mg/hr) and titrate to maintain desired blood pressure. Infusion Site Changes: Change infusion site every 12 hours if administered via peripheral vein.
Impaired Cardiac, Hepatic, or Renal Function: Monitor closely when titrating nicardipine hydrochloride injection in patients with congestive heart failure or impaired hepatic or renal function [see Warnings and Precautions (5.4, 5.5 and 5.6)].
2.6 Transfer to Oral Antihypertensive Agents
2.6 Transfer to Oral Antihypertensive Agents If treatment includes transfer to an oral antihypertensive agent other than nicardipine capsules, initiate oral therapy upon discontinuation of nicardipine hydrochloride injection. When switching to a TID regimen of nicardipine capsules, administer the first dose 1 hour prior to discontinuation of the infusion.
Dosing: Altered kidney function
Impaired Cardiac, Hepatic, or Renal Function: Monitor closely when titrating nicardipine hydrochloride injection in patients with congestive heart failure or impaired hepatic or renal function [see Warnings and Precautions (5.4 , 5.5 and 5.6) ].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and efficacy in patients under the age of 18 have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use The steady-state pharmacokinetics of nicardipine are similar in elderly hypertensive patients (greater than 65 years) and young healthy adults. Clinical studies of nicardipine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and concomitant disease of other drug therapy.
Administration
2.2 Inspection and Preparation Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use the solution if particulate matter, precipitate, or crystallization is present, or if the container appears damaged. Single Dose Vials Dilution Single dose vials must be diluted before infusion. Each vial (25 mg) must be diluted with 240 mL of compatible intravenous fluid (see below), resulting in 250 mL of solution at a concentration of 0.1 mg/mL. Compatability Nicardipine hydrochloride injection has been found compatible and stable in polyvinyl chloride containers for 24 hours at controlled room temperature with: Dextrose (5%) Injection, USP Dextrose (5%) and Sodium Chloride (0.45%) Injection, USP Dextrose (5%) and Sodium Chloride (0.9%) Injection, USP Dextrose (5%) with 40 mEq Potassium, USP Sodium Chloride (0.45%) Injection, USP Sodium Chloride (0.9%) Injection, USP Nicardipine hydrochloride is not compatible with Sodium Bicarbonate (5%) Injection, USP or Lactated Ringer’s Injection, USP.
2.3 Dosage as a Substitute for Oral Nicardipine Therapy The intravenous infusion rate required to produce an average plasma concentration equivalent to a given oral dose at steady state is shown in the following table: Oral Nicardipine Dose Equivalent Intravenous Infusion Rate 20 mg q8h 0.5 mg/hr 30 mg q8h 1.2 mg/hr 40 mg q8h 2.2 mg/hr
2.5 Conditions Requiring Infusion Adjustment Hypotension or Tachycardia: In case of hypotension or tachycardia, discontinue infusion. When blood pressure and heart rate stabilize, restart infusion at low doses such as 30 mL/hr to 50 mL/hr (3 mg/hr to 5 mg/hr) and titrate to maintain desired blood pressure. Infusion Site Changes: Change infusion site every 12 hours if administered via peripheral vein. Impaired Cardiac, Hepatic, or Renal Function: Monitor closely when titrating nicardipine hydrochloride injection in patients with congestive heart failure or impaired hepatic or renal function [see Warnings and Precautions (5.4 , 5.5 and 5.6) ].
US FDA labelDosage forms
Philippines
- ) solution for injection: 1 mg/1 mL (2 mg/2 mL, 1 mg/mL (10 mg/10 mL, 1 mg/mL (2 mg/2 mL, 1 mg/mL (2 mg/2 mL and 10 mg/10 mL, 1 mg/mL (20 mg/20 mL, 1 mg/mL (5 mg/5 mL, 10 mg/10 mL, 20 mg/20 mL, 10 mg/10 mL (1 mg/mL
- Solution for iv infusion: 1 mg/mL, 10 mg/10 mL
- Solution for injection: 1 mg/mL
- ) solution for i.v infusion: 1 mg/mL (10 mg/10 mL
- ) solution for i.v. infusion: 1 mg/mL (10 mg/10 mL
- ) solution for injection for iv infusion: 1 mg/mL (10 mg/10 mL
- )solution for injection: 1 mg/mL(10 mg/10 mL
- )solution for iv infusion: 1 mg/mL (10 mg/mL
- Solution for i.v. infusion: 1 mg/mL
Registered products in the Philippines
127 products registered with the Food and Drug Administration (FDA) Philippines list Nicardipine as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Nicardipine Hydochloride (1 product). Products registered under these spellings are included in the table and marked.
All registered products127
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AenicaNicardipine hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (I.V. Infusion)Type I amber glass ampoule x 10 mL (net content) (Box of 5's) | RxVAT-exempt | Furen Pharmaceutical Group Co., Ltd.China | Dynasty PharmaceuticalsImporter: Euro-Care Products Philippines | DRP-10412-05 | Sep 23, 2031 | |
AfreedipineNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV Infusion)Type I Amber Glass Ampoule x 10 mL (Box of 5's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-11154-04 | Feb 11, 2027 | |
AgynapinNicardipine Hydrochloride | 1 mg/mL Solution for Iv InfusionUSP Type I Amber Coloured Glass Ampoule X 10 mL (Box of 5’s in PVC Plastic Tray) | RxVAT-exempt | Furen Pharmaceutical Group Co., Ltd.China | Aglobal Care, Inc. | DRP-10088 | May 15, 2030 | |
ArdipinNicardipine Hydrochloride | 1 mg/mL Solution For Iv InfusionUsp Type I Amber Coloured Glass Ampoule X 10 mL (Box Of 5’s In PVC Plastic Tray) | RxVAT-exempt | Furen Pharmaceutical Group Co., Ltd.China | Macropharma CorporationImporter: Aglobal Care, Inc. | DRP-10088-03 | Feb 9, 2037 | |
BlicardeneNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV Infusion)Type I Amber Glass Ampoule x 10 mL (Box of 5's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-11154-12 | Feb 11, 2027 | |
BlicarpineNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV Infusion)Type I Ambel Glass Ampoule x 10 mL (Box of 5's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | CDMED Pharmecutical and Medical SupplyImporter: Afree Pharmaceutical Distribution Corp. | DRP-11154-11 | Feb 11, 2027 | |
BlinicNicardipine Hydrochloride | 1mg/mL (10mg/10mL) Solution For Injection (IV Infusion)Type I Amber Glass Ampoule x 10 mL (Box of 5's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Afree Pharmaceutical Distribution CorpImporter: Afree Pharmaceutical Distribution Corp. | DRP-11154 | Feb 11, 2027 | |
Blu-NirciaNicardipine Hydrochloride | 1 mg/ mL (10 mg/10 mL) Solution For Injection (IV)10 mL Amber Coloured USP Type-1 Glass Ampoule (Box of 5's) | RxVAT-exempt | Cooper Pharma LimitedIndia | Blu EnterprisesImporter: Ambica International Corporation | DRP-9084-06 | Aug 24, 2030 | |
CanelineNicardipine Hydrochloride | 1 mg/ mL (10 mg/ 10 mL ) Solution for Injection (I.V.)USP Type I Amber Glass Ampoule in Clear and Colorless PVC Tray x 10 mL (Box of 10’s) | RxVAT-exempt | AJU PHARM CO. LTD.Republic of Korea | GREENCORE PHARMA INC.Importer: TRIPLE TACT IMPORT & EXPORT CORP. | DRP-8442-01 | Nov 24, 2027 | |
CardemefNicardipine Hydrochloride | 1mg/mL (10mg/10mL) Solution for Injection (IV Infusion)Type I Amber Glass Ampoule x 10 mL (Box of 5's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Josmef EnterprisesImporter: Afree Pharmaceutical Distribution Corp. | DRP-11154-18 | Feb 11, 2027 | |
CardepineNicardipine hydrochloride | 1 mg/1 mL (2 mg/2 mL) Solution for Injection (IV)Amber Glass Ampoule x 2 mL (Box of 10's) | RxVAT-exempt | Amherst Parenterals, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY13463 | Feb 11, 2030 | |
CardepineNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV)Type I Amber Glass Ampoule with white dot x 10 mL (Box of 5's) | RxVAT-exempt | Amherst Parenterals, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY14274 | Oct 29, 2030 | |
CardeviaNicardipine Hydrochloride | 1 mg / mL Solution for IV InfusionUSP Type I Amber Glass Ampoule x 10 mL (Box of 5 ampoules x 10 mL in Blister Tray) | RxVAT-exempt | Scott-Edil Pharmacia Limited(H.P.) India | Northmed Pharma and Medical Supplies DistributionImporter: Pharmakon Biotec Inc. | DRP-14434-05 | Feb 15, 2028 | |
CardezNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV)10 mL USP Type I Amber Glass Ampoule (Box of 5’s) | RxVAT-exempt | Cooper Pharma LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-9084-02 | Aug 24, 2030 | |
Cardi-SNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV)10 mL USP Type I Amber Glass Ampoule (Box of 5’s) | RxVAT-exempt | Cooper Pharma LimitedIndia | Starpharm, Inc.Importer: Ambica International Corporation | DRP-9084-01 | Aug 24, 2030 | |
CardiconNicardipine hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (I.V. Infusion)Type I amber glass ampoule x 10 mL (net content) (Box of 5's) | RxVAT-exempt | Furen Pharmaceutical Group Co., Ltd.China | D'Conner PharmaImporter: Euro-Care Products Philippines | DRP-10412-03 | Sep 23, 2031 | |
CardigenNicardipine Hydrochloride | 1 mg / mL Solution for IV InfusionUSP Type I amber glass ampoule x 10 mL (Box of 5 ampoules x 10 mL in plastic tray) | RxVAT-exempt | Mason PharmaIndia | Genzen Pharmaceutical TradingImporter: Finstad Inc. | DRP-13161-01 | Dec 12, 2027 | |
CardilonNicardipine Hydrochloride | 1 mg/mL Solution for InjectionUSP Type I Amber Glass Ampoule x 2 mL (Box of 1's and 5's); USP Type I Amber Glass Ampoule x 10 mL (Box of 1's and 5's) | RxVAT-exempt | Norris Medicines LimitedIndia | Vivilon Pharmaceuticals Inc.Importer: Medethix, Inc.Trader: Alvita Pharma Private Limited | DRP-5308-01 | Oct 23, 2028 | |
CardimedNicardipine Hydrochloride | 1 mg/mL Solution for InjectionUSP Type I Amber Glass Ampoule x 2 mL (Box of 1's and 5's); USP Type I Amber Glass Ampoule x 10 mL (Box of 1's and 5's) | RxVAT-exempt | Norris Medicines LimitedIndia | Medhaus Pharma, IncorporatedImporter: Medethix, Inc.Trader: Alvita Pharma Private Limited | DRP-5308-02 | Oct 23, 2028 | |
1 mg/mL (10 mg/10 mL) Solution for Injection (IV)Clear Type I Glass Ampoule x 10 mL (Box of 1's) | Rx | Kwality Pharmaceuticals Ltd.India | Seapharma International, Inc.Importer: Pharma-Surrey International, Inc. | DRP-7066-01 | Feb 27, 2027 | ||
CardinovaNicardipine Hydrochloride | 1 mg/mL (10mg/10mL) Solution for Injection (IV Infusion)Type I Amber Glass Ampoule x 10mL (Box of 5's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Medinova Pharmaceutical Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-11154-05 | Feb 11, 2027 | |
CardiobestNicardipine hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (I.V. Infusion)Type I amber glass ampoule x 10 mL (net content) (Box of 5's) | RxVAT-exempt | Furen Pharmaceutical Group Co., Ltd.China | Best ClearImporter: Euro-Care Products Philippines | DRP-10412-04 | Sep 23, 2031 | |
CardiobideNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution For Injection10 mL USP Type I Amber Glass Ampoule (Box of 5's) | RxVAT-exempt | Cooper Pharma LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-9804-01 | Jul 31, 2037 | |
CardiobideNicardipine Hydrochloride | 1 mg/mL (2 mg/2 mL) Solution for Injection2 mL USP Type I Amber Glass Ampoule (Box of 5's) | RxVAT-exempt | Cooper Pharma LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-9803-01 | Oct 28, 2031 | |
CardionidNicardipine hydrochloride | 1 mg/mL (10mg/10mL) Solution for Injection (IV)USP Type 1 Amber Glass Ampoule x 10 mL in a plastic tray x 5's (Box of 5's) | RxVAT-exempt | Swiss Parenterals Ltd.India | Endure Medical, Inc. | DR-XY45528 | Jul 27, 2031 | |
CardionidNicardipine Hydrochloride | 1 mg/mL (2 mg/2mL) Solution for Injection (IV)USP Type I amber glass ampoule x 2 mL (10 ampoules in clear PVC tray) (Box of 10's) | RxVAT-exempt | Swiss Parenterals Ltd.India | Endure Medical, Inc. | DR-XY46903 | Jun 26, 2030 | |
CardiovinNicardipine Hydrochloride | 1mg/mL (10mg/10mL) Solution for I.V. Infusion10 mL Type I amber glass ampoule in PVC tray x 5's (Box of 5's) | RxVAT-exempt | Guizhou Tiandi Pharmaceutical Co., Ltd.China | MDB Pharma TradingImporter: AMB HK Enterprises Inc. | DRP-16013-04 | Dec 16, 2029 | |
CardiphilNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for I.V Infusion10 mL Type I amber glass ampoule in PVC tray x 5’s (Box of 5’s) | RxVAT-exempt | Guizhou Tiandi Pharmaceutical Co., Ltd.China | Philrx Pharma Inc.Importer: Amb Hk Enterprises Inc. | DRP-16013-02 | Dec 16, 2029 | |
CardisonNicardipine hydrochloride | 1 mg / mL (10 mg/10 mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule in PVC/PVDC Tray (Box of 10’s) | RxVAT-exempt | BCWorld Pharm. Co., Ltd.Republic of Korea | Jackson Pharmaceuticals Inc.Importer: JLT Pharma Inc. | DRP-14737-08 | Oct 13, 2031 | |
CardisonNicardipine hydrochloride | 10 mg/ 10 mL (1 mg/mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule in PVC/PVDC Tray Box of 10's | RxVAT-exempt | Dongkwang Pharm. Co., Ltd.Republic of Korea | Jackson Pharmaceuticals Inc.Importer: JLT Pharma Inc. | DRP-8014-13 | Aug 17, 2027 | |
CardivineNicardipine Hydrochloride | 1 mg /mL (10 mg/10 mL) Solution for I.V Infusion10 mL Type I amber glass ampoule in PVC tray x 5's (Box of 5’s) | RxVAT-exempt | Guizhou Tiandi Pharmaceutical Co., Ltd.China | Vintel Med EnterprisesImporter: AMB HK Enterprises Inc. | DRP-16013-01 | Dec 16, 2029 | |
CardizefNicardipine Hydrochloride | 10 mg/ 10 mL (1 mg/mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule in PVC/PVDC Tray (Box of 10's) | RxVAT-exempt | Dongkwang Pharma. Co., Ltd.Republic of Korea | Metro Pharma Philippines Inc.Importer: JLT Pharma, Inc. | DRP-8014-07 | Aug 17, 2027 | |
CardowinNicardipine hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV)Clear Type I Glass Ampoule x 10 mL (Box of 1's) | RxVAT-exempt | Kwality Pharmaceuticals Ltd.India | Pharma-Surrey International, Inc. | DRP-7066 | Feb 27, 2032 | |
CarenaNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV)10 mL Amber Coloured USP Type-1 Glass Ampoule (Box of 5’s) | RxVAT-exempt | Cooper Pharma LimitedIndia | Pro Medica Inc.Importer: Ambica International Corporation | DRP-9084-07 | Aug 24, 2030 | |
CarimaxNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV)Type I Borosilicate Amber Glass Ampoule x 10 mL (Box of 5's) | RxVAT-exempt | PT BernofarmIndonesia | Dreamax Life Sciences IncorporatedImporter: Dreamax IncorporatedTrader: PT Infion | DRP-10923-01 | Dec 17, 2026 | |
DicarpineNicardipine Hydrochloride | 1 mg / mL Solution for IV InfusionUSP Type I Amber Glass Ampoule x 10 mL (Box of 5 ampoules x 10 mL in Blister Tray) | RxVAT-exempt | Scott-Edil Pharmacia LimitedIndia | CDMED Pharmaceutical & Medical SupplyImporter: Pharmakon Biotec Inc. | DRP-14434-02 | Feb 15, 2028 | |
EntigardNicardipine Hydrochloride | 10 mg/ 10 mL (1 mg/mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule in PVC/PVDC Tray (Box of 10's) | RxVAT-exempt | Dongkwang Pharma. Co., Ltd.Republic of Korea | Amediqo Phils., Inc.Importer: JLT Pharma, Inc. | DRP-8014-01 | Aug 17, 2027 | |
EucardipineNicardipine hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (I.V. Infusion)Type I amber glass ampoule x 10 mL (net content) (Box of 5's) | RxVAT-exempt | Furen Pharmaceutical Group Co., Ltd.China | Euro-Care Products Philippines | DRP-10412 | Sep 23, 2031 | |
ExecardNicardipine Hydrochloride | 1mg/mL (10mg/10mL) Solution for Injection (IV Infusion)Type I Amber Glass Ampoule x 10 mL (Box of 5's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | HLM Pharmaceutical Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-11154-13 | Feb 11, 2027 | |
FamoginNicardipine hydrochloride | 1 mg/mL Solution for IV InfusionUSP Type I colorless glass ampoule in PVC Tray x 2 mL (Box of 1's, 5's and 10's); USP Type I colorless glass ampoule in PVC Tray x 10 mL (Box of 1's, 5's and 10's) | RxVAT-exempt | Kilitch Drugs (India) Ltd.India | Ambitech Pharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11606-01 | Apr 6, 2027 | |
GocardNicardipine Hydrochloride | 10 mg/ 10 mL (1 mg/mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule in PVC/PVDC Tray (Box of 10's) | RxVAT-exempt | Dongkwang Pharma Co., Ltd.Republic of Korea | Applied Pharmaceutical Distribution Inc.Importer: JLT Pharma, Inc. | DRP-8014-08 | Aug 17, 2027 | |
GocardipineNicardipine Hydrochloride | 10 mg / 10 mL (1 mg / mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule in PVC/PVDC Tray (Box of 10's) | RxVAT-exempt | Dongkwang Pharma Co., Ltd.Republic of Korea | Applied Pharmaceutical Distribution Inc.Importer: JLT Pharma, Inc. | DRP-8014-09 | Aug 17, 2027 | |
HycarNicardipine Hydrochloride | 1 mg/mL Solution for Injection (IV)USP Type I Amber Glass Ampoule x 2 mL (Box of 1's); USP Type I Amber Glass Ampoule x 2 mL (Box of 5's); USP Type I Amber Glass Ampoule x 10 mL (Box of 1's); USP Type I Amber Glass Ampoule x 10 mL (Box of 5's) | RxVAT-exempt | Norris Medicines LimitedIndia | I.E. Medica, Inc.Importer: Medethix, Inc.Trader: Alvita Pharma Private Limited | DRP-5308-04 | Oct 23, 2028 | |
Icard IVNicardipine Hydrochloride | 1 mg/ mL (10 mg/ 10 mL ) Solution for Injection (I.V.)USP Type I Amber Glass Ampoule in Clear and Colorless PVC Tray x 10 mL (Box of 10’s) | RxVAT-exempt | AJU PHARM CO. LTD.Republic of Korea | AMEDIQO PHILS., INC.Importer: TRIPLE TACT IMPORT & EXPORT CORP. | DRP-8442-03 | Nov 24, 2027 | |
KalpecorNicardipine Hydrochloride | 1mg/mL (2mg/2mL) Solution for Injection (IV)Type I Amber Glass Ampoule x 2mL (Box of 10’s) | RxVAT-exempt | Jiangsu Ruinian Qianjin Pharmaceutical Co.,LtdChina | Global PharmatradeTrader: Mecechem (Wuxi) Co., Ltd. | DR-XY44575 | Oct 28, 2031 | |
KardianNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution For Injection10 mL USP Type I Amber Glass Ampoule (Box of 5's) | RxVAT-exempt | Cooper Pharma Ltd.India | Uni-Pharma Phils., IncImporter: Ambica International Corporation | DRP-9804-02 | Aug 18, 2037 | |
KenzipineNicardipine hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule in PVC/PVDC Tray (Box of 10’s) | RxVAT-exempt | BCWorld Pharm. Co., Ltd.Republic of Korea | Bell-Kenz Pharma Inc.Importer: JLT Pharma Inc. | DRP-14737-10 | Oct 13, 2031 | |
KenzipineNicardipine Hydrochloride | 10 mg/ 10 mL (1 mg/mL) Solution for Injection (IV)USP Type 1 Amber Glass Ampoule in PVC/PVDC Tray (Box of 10's) | RxVAT-exempt | Dongkwang Pharma. Co., Ltd.Republic of Korea | Bell-Kenz Pharma Inc.Importer: JLT Pharma, Inc. | DRP-8014-04 | Aug 17, 2027 | |
MadexcardNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV)10 mL USP Type I Amber Glass Ampoule (Box of 5’s) | RxVAT-exempt | Cooper Pharma LimitedIndia | Madecs Pharma CorporationImporter: Ambica International Corporation | DRP-9084-03 | Aug 24, 2030 | |
MardepineNicardipine hydrochloride | 10 mg/ 10 mL (1 mg/mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule in PVC/PVDC Tray (Box of 10's) | RxVAT-exempt | Dongkwang Pharm. Co., Ltd.Republic of Korea | Marcburg Philippines Inc.Importer: JLT Pharma, Inc. | DRP-8014-11 | Aug 17, 2027 | |
MasopineNicardipine Hydrochloride | 1mg/mL Solution for IV InfusionUSP Type I amber glass ampoule x 10 mL (Box of 5 ampoules x 10 mL in plastic tray) | RxVAT-exempt | Mason PharmaIndia | Finstad Inc. | DRP-13161 | Dec 12, 2027 | |
NatripineNicardipine Hydrochloride | 1 mg/ mL(10 mg/ 10 mL )Solution for Injection (I.V.)USP Type I Amber Glass Ampoule in Clear and Colorless PVC Tray x 10 mL (Box of 10’s) | RxVAT-exempt | AJU PHARM CO. LTD.Republic of Korea | TRIPLE TACT IMPORT & EXPORT CORP. | DRP-8442 | Nov 24, 2027 | |
NatripineNicardipine hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV)Clear Type I Glass Ampoule x 10 mL (Box of 1's) | RxVAT-exempt | Kwality Pharmaceuticals Ltd.India | Triple Tact Import & Export Corp.Importer: Pharma-Surrey International, Inc. | DRP-7066-03 | Feb 27, 2027 | |
NewnicardNicardipine hydrochloride | 1 mg/mL Solution for IV InfusionUSP Type I colorless glass ampoule in PVC Tray x 10 mL (Box of 5's and 10's) | RxVAT-exempt | Kilitch Drugs (India) Ltd.India | Newman Pharmaceuticals CorporationImporter: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11606-02 | Apr 6, 2027 | |
NicablocNicardipine Hydrochloride | 1 mg/ml Solution for IV InfusionUSP Type I Amber Coloured Glass Ampoule x 10 mL (Box of 5’s in PVC Plastic Tray) | RxVAT-exempt | Furen Pharmaceutical Group Co., Ltd.China | The Cathay YSS Distributors Co., Inc.Importer: Aglobal Care, Inc. | DRP-10088-04 | May 15, 2030 | |
NicafarNicardipine Hydrochloride | 1 mg / mL Solution for IV InfusionUSP Type I Amber Glass Ampoule x 10 mL (Box of 5 ampoules x 10 mL in Blister Tray) | RxVAT-exempt | Scott-Edil Pharmacia LimitedIndia | Pharmakon Biotec Inc. | DRP-14434 | Feb 15, 2028 | |
NicafarNicardipine Hydrochloride | 1mg/mL Solution For IV InfusionUSP Type I Amber Glass Ampoule x 10 mL (Box of 5 ampoules x 10 mL in blister tray) | RxVAT-exempt | Scott-Edil Pharmacia LimitedIndia | Pharmakon Biotec Inc. | DR-XY48619 | Feb 15, 2028 | |
NicapedzNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution For Injection10 mL USP Type I Amber Glass Ampoule (Box of 5's) | RxVAT-exempt | Cooper Pharma LimitedIndia | Ambica International Corporation | DRP-9804 | Jun 10, 2031 | |
NicapedzNicardipine Hydrochloride | 1 mg/mL (2 mg/2 mL) Solution for Injection2 mL USP Type I Amber Glass Ampoule (Box of 5’s) | RxVAT-exempt | Cooper Pharma LimitedIndia | Ambica International Corporation | DRP-9803 | Jun 10, 2031 | |
NicaproNicardipine Hydrochloride | 1mg/mL (10mg/10mL) Solution for Injection (IV Infusion)Type I Amber Glass Ampoule x 10mL (Box of 5's) | RxVAT-exempt | — | Importer: Amediqo Phils., Inc. | DRP-11154-07 | Feb 11, 2027 | |
NicarcentNicardipine hydrochloride | 1 mg / mL (10 mg/10 mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule in PVC/ PVDC Tray (Box of 10’s) | RxVAT-exempt | BCWorld Pharm. Co., Ltd.Republic of Korea | Central West Medicale Inc.Importer: JLT Pharma Inc. | DRP-14737-06 | Oct 13, 2031 | |
NicarcentNicardipine Hydrochloride | 10 mg/10 mL (1 mg/mL) Solution for Injection (I.V.)USP Type I Amber Glass Ampoule in PVC/PVDC Tray (Box of 10's) | RxVAT-exempt | Dongkwang Pharma. Co., Ltd.Republic of Korea | Central West Medicale Inc.Importer: JLT Pharma Inc. | DRP-8014-14 | Aug 17, 2027 | |
NicarchelNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV Infusion)Type I Amber Glass Ampoule x 10 mL (Box of 5's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Sonchel Pharma DistributorsImporter: Afree Pharmaceutical Distribution Corp. | DRP-11154-01 | Feb 11, 2027 | |
NicardaceNicardipine (as hydrochloride) | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV)10 mL Amber Coloured USP Type-1 Glass Ampoule (Box of 5’s) | RxVAT-exempt | Cooper Pharma LimitedIndia | One Technodrug Life Sciences Inc.Importer: Ambica International Corporation | DRP-9084-08 | Aug 24, 2030 | |
NicardenNicardipine Hydrochloride | 1mg/mL (10mg/10mL) Solution for Injection (IV Infusion)Type I Amber Glass Ampoule x 10mL (Box of 5's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | JMN Brothers Pharma Limited Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-11154-02 | Feb 11, 2027 | |
NicardilexNicardipine Hydrochloride | 1 mg/mL (2 mg/2 mL and 10 mg/10 mL) Solution for Injection (IV)USP Type I Amber Colored Glass Ampoule x 2 mL and 10 mL (Box of 5's and 10's) | RxVAT-exempt | United Biotech Pvt. Ltd.India | Delex Pharma International, Inc. | DRP-6940 | Dec 1, 2031 | |
NicardilexNicardipine hydrochloride | 1 mg/mL (20 mg/20 mL) Solution for Injection (I.V.)20 mL-net content USP Type I amber glass vial with grey glass vial butyl rubber stopper and aluminum seal with green plastic flip-off cap (Box of 1's) | RxVAT-exempt | United Biotech Pvt. Ltd.India | Delex Pharma International, Inc. | DRP-15060 | Apr 1, 2029 | |
NicardiMaxNicardipine Hydrochloride | 1 mg/mL (10mg/10mL) Solution for Injection (IV)Type I Borosilicate Amber Glass Ampoule x 10 mL (Box of 5's) | RxVAT-exempt | PT. BernofarmIndonesia | Dreamax Life Sciences IncorporatedImporter: Dreamax IncorporatedTrader: PT. Infion | DRP-10923-02 | Dec 17, 2026 | |
NicardimeNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV)Clear Type I Glass Ampoule x 10 mL (Box of 1's) | RxVAT-exempt | Kwality Pharmaceuticals Ltd.India | Pharmadyme Philippines, Inc.Importer: Pharma-Surrey International, Inc. | DRP-7066-02 | Feb 27, 2027 | |
NicardimedsNicardipine hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (I.V. Infusion)Type I amber glass ampoule x 10 mL (net content) (Box of 5's) | RxVAT-exempt | Furen Pharmaceutical Group Co., Ltd.China | Asianmeds, Inc.Importer: Euro-Care Products Philippines | DRP-10412-01 | Sep 23, 2036 | |
NicardinNicardipine hydrochloride | 1 mg / mL (10 mg/10 mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule in PVC/ PVDC Tray (Box of 10’s) | RxVAT-exempt | BC World Pharm. Co., Ltd.Republic of Korea | Pharmasia-Cuvest IncorporatedImporter: JLT Pharma Inc. | DRP-14737-02 | Oct 13, 2031 | |
NicardinNicardipine hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (I.V.)USP Type I Amber Glass Ampoule in PVC/PVDC Tray (10 mL x Box of 10's; 5mL x Box of 25's; and 20 mL x Box of 10's) | RxVAT-exempt | BC World Pharm Co., Ltd.Korea | PharmAsia-Cuvest, IncorporatedImporter: JLT Pharma Inc. | DRP-14737 | Jan 15, 2031 | |
NicardisanNicardipine Hydrochloride | 1 mg/mL Solution for IV InfusionUSP Type I Amber Coloured Glass Ampoule x 10 mL (Box of 5’s in PVC Plastic Tray) | RxVAT-exempt | Furen Pharmaceutical Group Co., Ltd.China | Sannovex Pharmaceutical DistributorImporter: Aglobal Care, Inc. | DRP-10088-07 | Jun 2, 2031 | |
NicarditechNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV)10 mL Amber coloured USP Type -1 Glass Ampoule (Box of 5’s) | RxVAT-exempt | Cooper Pharma LimitedIndia | One Technodrug Life Sciences Inc.Importer: Ambica International Corporation | DRP-9084-05 | Aug 24, 2030 | |
NicardivinNicardipine hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (I.V. Infusion)Type I amber glass ampoule x 10 mL (net content) (Box of 5's) | RxVAT-exempt | Furen Pharmaceutical Group Co., Ltd.China | MDB Pharma TradingImporter: Euro-Care Products Philippines | DRP-10412-02 | Sep 23, 2036 | |
NicardixNicardipine Hydrochloride | 1 mg / ml (10 mg / 10 ml) Solution for Injection (IV Infusion)10 mL Type I Amber Glass Ampoule Clear PVC Tray x 5's (Box of 5's) | RxVAT-exempt | Scott-Edil Pharmacia LimitedIndia | Euroasia Pharmaceuticals. Inc.Importer: Teramedix Pharma Trading Inc. | DRP-12597-01 | Sep 12, 2027 | |
NicardoNicardipine hydrochloride | 1 mg / mL (10 mg/10 mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule in PVC/ PVDC Tray (Box of 10’s) | RxVAT-exempt | BCWorld Pharm. Co., Ltd.Republic of Korea | AGCC MarketingImporter: JLT Pharma Inc. | DRP-14737-09 | Oct 13, 2031 | |
NicardoNicardipine Hydrochloride | 1 mg/mL (2 mg/2 mL) Solution for Injection2 mL USP Type I Amber Glass Ampoule (Box of 5’s) | RxVAT-exempt | Cooper Pharma LimitedIndia | AGCC MarketingImporter: Ambica International Corporation | DRP-9803-02 | Jun 10, 2031 | |
NicardoNicardipine Hydrochloride | 10 mg/10 mL (1 mg/mL) Solution for Injection (IV)USP Type 1 Amber Glass Ampoule in PVC/PVDC Tray (Box of 10's) | RxVAT-exempt | Dongkwang Pharma. Co., Ltd.Republic of Korea | AGCC MarketingImporter: JLT Pharma, Inc. | DRP-8014-05 | Aug 17, 2027 | |
NicardripNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution For Injection10 mL USP Type I Amber Glass Ampoule (Box of 5's) | RxVAT-exempt | Cooper Pharma LimitedIndia | AGCC MARKETINGImporter: Ambica International Corporation | DRP-9804-03 | Aug 12, 2037 | |
NicarduzNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution For Injection (IV Infusion)10 mL Type I Amber Glass Ampoule in Clear PVC Tray x 5's (Box of 5's) | RxVAT-exempt | Scott-Edil Pharmacia LimitedIndia | Teramedix Pharma Trading, Inc. | DRP-12597 | Sep 12, 2027 | |
NicarfionNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV)Type I Borosilicate Amber Glass Ampoule x 10 mL (Box of 5's) | RxVAT-exempt | PT. BernofarmIndonesia | Dreamax Incorporated | DRP-10923 | Dec 17, 2026 | |
NicarfreeNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV Infusion)Type I Amber Glass Ampoule x 10 mL (Box of 5's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-11154-03 | Feb 11, 2027 | |
NicargenNicardipine hydrochloride | 1 mg / mL (5 mg/5 mL, 10 mg/10 mL, 20 mg/20 mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule in PVC/PVDC Tray x 10 (Box of 10's) | RxVAT-exempt | BCWorld Pharm. Co., Ltd.Republic of Korea | Ellebasy Medicale Group Inc.Importer: JLT Pharma Inc. | DRP-14737-12 | Jan 15, 2031 | |
NicargenNicardipine hydrochloride | 10 mg/10 mL (1 mg/mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule in PVC/PVDC Tray Box of 10's | RxVAT-exempt | Dongkwang Pharma. Co., Ltd.Republic of Korea | Innogen Pharmaceuticals, Inc.Importer: JLT Pharma, Inc. | DRP-8014-02 | Aug 17, 2027 | |
NicargioNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV Infusion)Type I amber glass ampoule x 10 mL (Box of 5's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Ellebasy Medicale TradingImporter: Afree Pharmaceutical Distribution Corp. | DRP-11154-08 | Feb 11, 2027 | |
NicarightNicardipine Hydrochloride | 1 mg/mL Solution for Injection (IV)USP Type I Amber Glass Ampoule x 2mL (Box of 1's and 5's); USP Type I Amber Glass ampoule x 10 mL (Box of 1's and 5's) | RxVAT-exempt | Norris Medicines LimitedIndia | Medethix, Inc.Trader: Alvita Pharma Private Limited | DRP-5308 | Oct 23, 2028 | |
Nicarllen-PE1Nicardipine Hydrochloride | 1 mg/ mL Solution For I.V. InfusionUSP Type I glass ampoule x 2 mL, 10 mL and 20 mL in PVC Tray (Box of 1’s, 5’s, and 10’s) | RxVAT-exempt | Penam Biosciences Pvt. Ltd.India | Ollen Pharm Trading Inc. | DRP-18897 | Sep 29, 2031 | |
NicarphilNicardipine Hydrochloride | 1 mg/mL Solution for Injection (IV)USP Type I Clear Glass Vial Ampoule x 10 mL (Box of 5's) | RxVAT-exempt | Ratnatris Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-17342 | Nov 19, 2030 | |
NicarpinNicardipine hydrochloride | 10 mg/ 10 mL Solution for IV InfusionType I Borosilicate brown glass ampoule x 10 mL (Box of 10's) | RxVAT-exempt | LABORATOIRE AGUETTANTFrance | THE CATHAY DRUG CO., INC. | DR-XY46728 | Oct 29, 2029 | |
NicarpineNicardipine Hydrochloride | 1 mg/ml (10 mg/ml)Solution for IV Infusion10ml Type I Amber Glass Ampoule (Box of 1's) (Box of 1's) | RxVAT-exempt | Ta fong Pharmaceutical Co.LtdTaiwan | Neo Care PhilippinesImporter: Neo care PhilippinesTrader: Pei Li Pharmaceutical Ind. Co.,Ltd | DRP-6947 | Nov 26, 2029 | |
NicarpureNicardipine Hydrochloride | 1 mg/mL Solution for IV InfusionUsp Type I Amber Coloured Glass Ampoule X 10 mL (Box of 5’s In PVC Plastic Tray) | RxVAT-exempt | Furen Pharmaceutical Group Co., Ltd.China | Bellus Life Solutions, Inc.Importer: Aglobal Care, Inc. | DRP-10088-05 | Apr 16, 2031 | |
NicarsaphNicardipine Hydrochloride | 1mg/mL Solution for IV InfusionUSP Type I colorless glass ampoule in PVC Tray x 2 mL (Box of 1's, 5's and 10's); USP Type I colorless glass ampoule in PVC Tray x 10 mL (Box of l's, 5's and 10's) | RxVAT-exempt | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11606 | Apr 6, 2027 | |
NicarsaveNicardipine Hydrochloride | 1 mg / mL Solution for IV InfusionUSP Type I Amber Coloured Glass Ampoule x 10 mL (Box of 5’s in PVC Plastic Tray) | RxVAT-exempt | Furen Pharmaceutical Group Co., LtdChina | Savelink Pharma and Trading Co.Importer: Aglobal Care, Inc. | DRP-10088-08 | May 15, 2030 | |
NicarSaveNicardipine hydrochloride | 1mg/mL (10mg/10ml) Solution for Injection (IV)Type I Glass Ampoule x 10 ml in PVC Tray (Box of 5's) | RxVAT-exempt | Maxitech Pharma (Pvt.) Ltd.Pakistan | Savelink Pharma and Trading Co.Importer: Accesspoint International Trading Inc. | DRP-17231-02 | Oct 22, 2030 | |
NicarsinNicardipine hydrochloride | 10 mg/ 10 mL (1 mg/mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule in PVC/PVDC tray Box of 10's | RxVAT-exempt | Dongkwang Pharma. Co., Ltd.Republic of Korea | Sincera Pharmaceutical CorporationImporter: JLT Pharma, Inc. | DRP-8014-12 | Aug 17, 2027 | |
NicarsonNicardipine Hydrochloride | 1 mg/mL (10 mg/ 10 mL) Solution for Injection (I.V.)USP Type 1 Amber Glass Ampoule in Clear and Colorless PVC Tray x 10 mL (Box of 10’s) | RxVAT-exempt | Aju Pharm Co. Ltd.Republic of Korea | Justright Healthcare Inc.Importer: Triple Tact Import & Export Corp. | DRP-8442-02 | Nov 24, 2027 | |
NicarsonNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule in PVC/PVDC Tray (Box of 10's) | RxVAT-exempt | BCWorld Pharm. Co., Ltd.Republic of Korea | Justright Healthcare Inc.Importer: JLT Pharma Inc. | DRP-14737-03 | Oct 13, 2031 | |
NicarvinNicardipine Hydrochloride | 1mg/mL (10mg/10mL) Solution for Injection (IV Infusion)Type I Amber Glass Ampoule x 10 mL (Box of 5's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Vintel Med EnterprisesImporter: Afree Pharmaceutical Distribution Corp. | DRP-11154-09 | Feb 11, 2027 | |
NicasanNicardipine Hydrochloride | 1mg/mL (10mg/10mL) Solution for Injection (IV Infusion)Type I amber glass ampoule x 10mL (Box of 5's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Sanimed Pharmaceuticals Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-11154-14 | Feb 11, 2027 | |
NicmeedNicardipine Hydrochloride | 1mg/mL (10mg/10mL) Solution for Injection (IV Infusion)Type I Amber Glass Ampoule x 10 mL (Box of 5's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Meedpharma Medical Supplies & Equipment DistributorImporter: Afree Pharmaceutical Distribution Corp. | DRP-11154-10 | Feb 11, 2027 | |
NikemNicardipine Hydrochloride | 1 mg / mL Solution for IV InfusionUSP Type I Amber Glass Ampoule x 10 mL (Box of 5 ampoules x 10 mL in Blister Tray) | RxVAT-exempt | Scott-Edil Pharmacia LimitedIndia | Alkem Laboratories CorporationImporter: Pharmakon Biotec Inc. | DRP-14434-01 | Feb 15, 2028 | |
NircaruNicardipine hydrochloride | 1 mg / mL (10 mg/10 mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule in PVC/ PVDC Tray (Box of 10’s) | RxVAT-exempt | BCWorld Pharm. Co., Ltd.Republic of Korea | Ellebasy Medicale TradingImporter: JLT Pharma Inc. | DRP-14737-11 | Oct 13, 2031 | |
NivacorNicardipine Hydrochloride | 1 mg / mL Solution for IV InfusionUSP Type I Amber Glass Ampoule x 10 mL (Box of 5 ampoules x 10 mL in Blister Tray) | RxVAT-exempt | Scott-Edil Pharmacia Limited(H.P.) India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-14434-04 | Feb 15, 2028 | |
NoneNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV Infusion)Type I Amber Glass Ampoule x 10 mL (Box of 5's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-11154-15 | Feb 11, 2027 | |
NoneNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV Infusion)Type I Amber Glass Ampoule x 10 mL (Box of 5's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Central West Medicale Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-11154-17 | Feb 11, 2027 | |
NoneNicardipine Hydrochloride | 1 mg/mL Solution for IV InfusionType I Amber glass ampoule (Box of 10's x 2mL; Box of 10's x 10mL) | RxVAT-exempt | Millimed Company LimitedThailand | Endure Medical, Inc. | DR-XY46890 | Jul 2, 2030 | |
NoneNicardipine Hydrochloride | 1mg/mL (10mg/10mL) Solution for Injection (IV Infusion)Type I amber glass ampoule x 10mL (Box of 5's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-11154-06 | Feb 11, 2027 | |
NoneNicardipine Hydrochloride | 1mg/mL (10mg/10mL) Solution for Injection (IV Infusion)Type I amber Glass Ampoule x 10mL (Box of 5's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-11154-16 | Feb 11, 2027 | |
NoneNicardipine hydrochloride | 1mg/mL (10mg/10mL) Solution for Injection (IV)Type I Glass Ampoule x 10 mL in PVC Tray (Box of 5's) | RxVAT-exempt | Maxitech Pharma (Pvt.) Ltd.Pakistan | Reta DrugImporter: Accesspoint International Trading Inc. | DRP-17231-01 | Oct 22, 2030 | |
NoticanzNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV)10 mL Amber Coloured USP Type-1 Glass Ampoule (Box of 5’s) | RxVAT-exempt | Cooper Pharma LimitedIndia | Ambica International Corporation | DRP-9084 | Aug 24, 2030 | |
NoticanzNicardipine Hydrochloride | 1 mg/mL (2 mg/2 mL) Solution for Injection (IV)2 mL USP Type I Amber Glass Ampoule (Box of 5’s) | RxVAT-exempt | Cooper Pharma LimitedIndia | Ambica International Corporation | DRP-9041 | Aug 18, 2030 | |
PhaxopineNicardipine Hydrochloride | 1 mg/ mL Solution for IV InfusionUSP Type I amber glass ampoule x 10 mL (Box of 5 ampoules x 10 mL in plastic tray) | RxVAT-exempt | Mason PharmaIndia | Pathfinder Pharmacy & DistributorImporter: Finstad Inc. | DRP-13161-03 | Dec 12, 2027 | |
PilldipineNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV)10 mL Amber Coloured USP Type-1 Glass Ampoule (Box of 5's) | RxVAT-exempt | Cooper Pharma LimitedIndia | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-9084-04 | Aug 24, 2030 | |
ProcardipineNicardipine hydrochloride | 10 mg/10 mL (1 mg/mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule in PVC/PVDC Tray Box of 10's | RxVAT-exempt | Dongkwang Pharma. Co., Ltd.Republic of Korea | Pro-jectable Pharmaceuticals Inc.Importer: JLT Pharma, Inc. | DRP-8014-06 | Aug 17, 2027 | |
RacardipineNicardipine Hydrochloride | 1mg/mL Solution for IV Infusion2 mL and 10 mL USP Type I clear glass ampoule (Box of 1’s, 5,’s, and 10’s) | RxVAT-exempt | Jiangsu Ruinian Qianjin Pharmaceutical Co., Ltd.China | Raquel Abbas Pharma Inc. | DRP-19101 | Oct 28, 2031 | |
RahdepineNicardipine hydrochloride | 1mg/mL (10mg/10mL) Solution for Injection (IV)I Glass Ampoule x 10mL in PVC Tray (Box of 5's) | RxVAT-exempt | Maxitech Pharma (Pvt) Ltd.Pakistan | Accesspoint International Trading Inc. | DRP-17231 | Oct 22, 2030 | |
Retacard-RNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection (IV Infusion)Type I Amber Glass Ampoule x 10 mL (Box of 5's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Reta DrugImporter: Afree Pharmaceutical Distribution Corp. | DRP-11154-19 | Feb 11, 2027 | |
SaguinlaxNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution For Injection (IV)Type I Amber Glass Ampoule x 10 mL in Plastic Tray (Box of 5's) | RxVAT-exempt | Samrudh Pharmaceuticals Pvt. Ltd.India | Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd. | DRP-18962 | Oct 19, 2031 | |
SalusnicarNicardipine Hydrochloride | 1 mg / mL Solution for IV InfusionUSP Type I amber glass ampoule x 10 mL (Box of 5 ampoules x 10 mL in plastic tray) | RxVAT-exempt | Mason PharmaIndia | Salusa Medical Supplies and Pharmaceuticals Inc.Importer: Finstad Inc. | DRP-13161-02 | Dec 12, 2027 | |
Saphnicar-AltNicardipine Hydrochloride | 1 mg/mL Solution For Injection (IV Infusion)Type I Colorless Glass Ampoule x 2 mL, 10 mL and 20 mL in PVC Tray (Box of 1's, 5's and 10's) | RxVAT-exempt | Althea Pharma Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-18963 | Oct 8, 2031 | |
TensiloNicardipine Hydrochloride | 1 mg/mL Solution For Injection (I.V.)Type I Clear colorless borosilicate glass vial with red halobutyl rubber stopper and green flip-off cap x 10 mL (Box of 2's) | RxVAT-exempt | PT. Pratapa NirmalaIndonesia | Exa Life Care Pharma Inc. | DR-XY48355 | Sep 29, 2027 | |
UnicardNicardipine hydrochloride | 1 mg / mL (10 mg/10 mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule in PVC/ PVDC Tray (Box of 10’s) | RxVAT-exempt | BCWorld Pharm. Co., Ltd.Republic of Korea | Uni-Pharma Phils., Inc.Importer: JLT Pharma Inc. | DRP-14737-07 | Oct 13, 2031 | |
UnicardNicardipine hydrochloride | 10 mg/ 10 mL (1 mg/mL) Solution for Injection (IV)USP Type 1 Amber Glass Ampoule in PVC/PVDC Tray (Box of 10's) | RxVAT-exempt | Dongkwang Pharma. Co., Ltd.Republic of Korea | Uni-Pharma Phils., Inc.Importer: JLT Pharma, Inc. | DRP-8014-03 | Aug 17, 2027 | |
VALCARDEXNicardipine Hydrochloride | 1 mg/ml (10 mg/10 ml) Solution for I.V. Infusion10 mL Type I amber glass ampoule in PVC tray x 5’s (Box of 5’s and 10’s) | RxVAT-exempt | Guizhou Tiandi Pharmaceutical Co., Ltd.China | SwissPharmatech Co.Importer: AMB HK Enterprises Inc. | DRP-16013-03 | Dec 16, 2029 | |
VeksiaNicardipine Hydrochloride | 1 mg / mL Solution for IV InfusionUSP Type I Amber Glass Ampoule x 10 mL (Box of 5 ampoules x 10 mL in Blister Tray) | RxVAT-exempt | Scott-Edil Pharmacia LimitedIndia | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-14434-03 | Feb 15, 2028 | |
ZicardNicardipine Hydrochloride | 1 mg/mL (10 mg/10 mL) Solution for Injection for IV InfusionAmber Glass Ampoule x 10 mL (net content). Protect from light. | RxVAT-exempt | AJU PHARM CO., LTD.Korea | Zyre Pharmaceuticals Corporation | DR-XY46850 | Mar 13, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Nicardipine hydrochloride is available in the following presentations: 25 mg nicardipine hydrochloride in 10 mL injection (2.5 mg/mL) in a single dose vial 25 mg/10 mL (2.5 mg/mL) single-dose vial (3)
Warnings/Precautions
- To reduce the possibility of venous thrombosis, phlebitis, and vascular impairment, do not use small veins, such as those on the dorsum of the hand or wrist. Avoid intraarterial administration or extravasation (5.7). To minimize the risk of peripheral venous irritation, change the site of infusion of nicardipine every 12 hours (5.7). Nicardipine is not a beta-blocker and therefore gives no protection against the dangers of abrupt beta-blocker withdrawal. Withdraw beta-blockers gradually (5.8). Closely monitor response in patients with angina (5.3), congestive heart failure (5.4), impaired hepatic function (5.5), portal hypertension (5.5), and renal impairment (5.6)
- and pheochromocytoma (5.9).
5.1 Excessive Pharmacologic Effects
5.1 Excessive Pharmacologic Effects In administrating nicardipine, close monitoring of blood pressure and heart rate is required. Nicardipine may occasionally produce symptomatic hypotension or tachycardia. Avoid systemic hypotension when administering the drug to patients who have sustained an acute cerebral infarction or hemorrhage.
5.2 Rapid Decreases in Blood Pressure
5.2 Rapid Decreases in Blood Pressure No clinical events have been reported suggestive of a too rapid decrease in blood pressure with nicardipine. However, as with any antihypertensive agent, blood pressure lowering should be accomplished over as long a time as is compatible with the patient's clinical status.
5.3 Use in Patients with Angina
5.3 Use in Patients with Angina Increases in frequency, duration, or severity of angina have been seen in chronic oral therapy with nicardipine capsules. Induction or exacerbation of angina has been seen in less than 1% of coronary artery disease patients treated with nicardipine. The mechanism of this effect has not been established.
5.4 Use in Patients with Congestive Heart Failure
5.4 Use in Patients with Congestive Heart Failure Nicardipine reduced afterload without impairing myocardial contractility in preliminary hemodynamic studies of CHF patients. However, in vitro and in some patients, a negative inotropic effect has been observed. Therefore, monitor vital signs carefully when using nicardipine, particularly in combination with a beta-blocker, in patients with CHF or significant left ventricular dysfunction.
5.5 Use in Patients with Impaired Hepatic Function
5.5 Use in Patients with Impaired Hepatic Function Since nicardipine is metabolized in the liver, consider lower dosages and closely monitor response. Nicardipine administered intravenously increased hepatic venous pressure gradient by 4 mmHg in cirrhotic patients at high doses (5 mg/20 min) in one study. Use caution in patients with portal hypertension.
5.6 Use in Patients with Impaired Renal Function
5.6 Use in Patients with Impaired Renal Function When nicardipine was given to mild-to-moderate hypertensive patients with moderate renal impairment, a significantly lower systemic clearance and higher AUC was observed. These results are consistent with those seen after oral administration of nicardipine. Careful dose titration is advised when treating patients with more than mild renal impairment.
5.7 Intravenous Infusion Site
5.7 Intravenous Infusion Site To reduce the possibility of venous thrombosis, phlebitis, local irritation, swelling, extravasation, and the rare occurrence of vascular impairment, administer drug through large peripheral veins or central veins rather than arteries or small peripheral veins, such as those on the dorsum of the hand or wrist. To minimize the risk of peripheral venous irritation, consider changing the site of the drug infusion every 12 hours.
5.8 Beta-Blocker Withdrawal
5.8 Beta-Blocker Withdrawal Nicardipine is not a beta-blocker and therefore gives no protection against the dangers of abrupt beta-blocker withdrawal. Withdraw beta-blockers gradually.
5.9 Use in Patients with Pheochromocytoma
5.9 Use in Patients with Pheochromocytoma Only limited clinical experience exists in use of nicardipine for patients with hypertension from pheochromocytoma.
Drug interactions
Cimetidine increases nicardipine plasma levels (7.3). Nicardipine may increase cyclosporine and tacrolimus plasma levels. Frequent monitoring of trough blood levels of cyclosporine and tacrolimus is recommended when co-administering nicardipine. (7.5, 7.6).
7.1 Antihypertensive Agents
7.1 Antihypertensive Agents Since nicardipine hydrochloride injection may be administered to patients already being treated with other medications, including other antihypertensive agents, careful monitoring of these patients is necessary to detect and to treat promptly any undesired effects from concomitant administration.
7.2 Beta-Blockers
7.2 Beta-Blockers In most patients, nicardipine hydrochloride injection can safely be used concomitantly with beta-blockers. However, monitor response carefully when combining nicardipine hydrochloride injection with a beta-blocker in the treatment of congestive heart failure patients [see Warnings and Precautions (5.4)].
7.3 Cimetidine
7.3 Cimetidine Cimetidine has been shown to increase nicardipine plasma concentrations with oral nicardipine administration. Carefully monitor patients receiving the two drugs concomitantly. Data with other histamine-2 antagonists are not available.
7.4 Digoxin
7.4 Digoxin Studies have shown that oral nicardipine usually does not alter digoxin plasma concentrations.
7.5 Cyclosporine
7.5 Cyclosporine Concomitant administration of oral or intravenous nicardipine and cyclosporine results in elevated plasma cyclosporine levels through nicardipine inhibition of hepatic microsomal enzymes, including CYP3A4. Monitor closely plasma concentrations of cyclosporine during nicardipine hydrochloride injection administration, and adjust the dose of cyclosporine accordingly.
7.6 Tacrolimus
7.6 Tacrolimus Concomitant administration of intravenous nicardipine and tacrolimus may result in elevated plasma tacrolimus levels through nicardipine inhibition of hepatic microsomal enzymes, including CYP3A4. Closely monitor plasma concentrations of tacrolimus during nicardipine administration, and adjust the dose of tacrolimus accordingly.
7.7 In Vitro Interaction
7.7 In Vitro Interaction The plasma protein binding of nicardipine was not altered when therapeutic concentrations of furosemide, propranolol, dipyridamole, warfarin, quinidine, or naproxen were added to human plasma in vitro.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Metabolism and Excretion Nicardipine has been shown to be rapidly and extensively metabolized by the hepatic cytochrome P450 enzymes, CYP2C8, 2D6, and 3A4.
Nicardipine does not induce or inhibit its own metabolism; however, nicardipine has been shown to inhibit certain cytochrome P450 enzymes (including CYP3A4, CYP2D6, CYP2C8, and CYP2C19).
Data with other histamine-2 antagonists are not available. 7.4 Digoxin Studies have shown that oral nicardipine usually does not alter digoxin plasma concentrations. 7.5 Cyclosporine Concomitant administration of oral or intravenous nicardipine and cyclosporine results in elevated plasma cyclosporine levels through nicardipine inhibition of hepatic microsomal enzymes, including CYP3A4.
Monitor closely plasma concentrations of cyclosporine during nicardipine hydrochloride injection administration, and adjust the dose of cyclosporine accordingly. 7.6 Tacrolimus Concomitant administration of intravenous nicardipine and tacrolimus may result in elevated plasma tacrolimus levels through nicardipine inhibition of hepatic microsomal enzymes, including CYP3A4.
Adverse reactions
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS Most common adverse reactions are headache (13%), hypotension (5%), tachycardia (4%) and nausea/vomiting (4%). To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Adverse Reactions Observed in Clinical Trials Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Two hundred forty-four patients participated in two multicenter, double-blind, placebo-controlled trials of nicardipine. Adverse experiences were generally not serious and most were expected consequences of vasodilation. Adverse reactions occasionally required dosage adjustment. Therapy was discontinued in approximately 12% of patients, mainly due to hypotension, headache, and tachycardia.
Adverse reactions that occurred more often on nicardipine than on placebo by at least 2% were headache (13%) and nausea/vomiting (4%). The following adverse reactions have been reported in clinical trials or in the literature during the use of intravenously administered nicardipine. Body as a Whole: fever, neck pain Cardiovascular: angina pectoris, atrioventricular block, ST segment depression, inverted T wave, deep-vein thrombophlebitis Digestive: dyspepsia Hemic and Lymphatic: thrombocytopenia Metabolic and Nutritional: hypophosphatemia, peripheral edema Nervous: confusion, hypertonia Respiratory: respiratory disorder Special Senses: conjunctivitis, ear disorder, tinnitus Urogenital: urinary frequency Sinus node dysfunction and myocardial infarction, which may be due to disease progression, have been seen in patients on chronic therapy with orally administered nicardipine.
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Pregnancy Category C. There are no adequate and well-controlled studies of nicardipine use in pregnant women. There are limited human data in pregnant women with pre-eclampsia and preterm labor. In animal reproduction and developmental toxicity studies, evidence of fetal harm was observed. Therefore use nicardipine during pregnancy only if the potential benefit justifies the potential risk to the fetus.
In reproduction studies conducted in rats and rabbits, increased embryolethality occurred when nicardipine was administered intravenously at doses equivalent to human intravenous doses of 1.6 (rats) and 0.32 mg/kg/day (rabbits). Increased embryolethality was also observed when nicardipine was administered orally to pregnant rabbits at a dose equivalent to a human oral dose of about 48 mg/kg/day (a dose 24 times the maximum recommended human oral dose and one associated with marked maternal body weight gain suppression).
At a lower oral dose, equivalent to a human dose of about 32 mg/kg/day (16 times the maximum recommended human oral dose), in a different strain of rabbit, there were no adverse effects on the fetus, though there was increased maternal mortality. There was no evidence of embryolethality or teratogenicity when pregnant rats were administered nicardipine orally at a dose equivalent to a human oral dose of about 16 mg/kg/day (8 times the MRHD); however, dystocia, reduced birth weight, reduced neonatal survival and reduced neonatal weight gain were reported [see Nonclinical Toxicology (13.3)].
Breastfeeding considerations
Lactation (US label) US FDA label
8.3 Nursing Mothers Nicardipine is minimally excreted into human milk. Among 18 infants exposed to nicardipine through breast milk in the postpartum period, calculated daily infant dose was less than 0.3 mcg and there were no adverse events observed. It is recommended that women who wish to breastfeed should not be given this drug.
In a study of 11 women who received oral nicardipine 4 days to 14 days postpartum, 4 women received immediate-release nicardipine 40 to 80 mg daily, 6 women received sustained-release nicardipine 100 mg to 150 mg daily, and one woman received intravenous nicardipine 120 mg daily. The peak milk concentration was 7.3 mcg/L (range 1.9 to 18.8), and the mean milk concentration was 4.4 mcg/L (range 1.3 to 13.8).
Infants received an average of 0.073% of the weight-adjusted maternal oral dose and 0.14% of the weight-adjusted maternal intravenous dose. In another study of seven women who received intravenous nicardipine for an average of 1.9 days in the immediate postpartum period as therapy for pre-eclampsia, 34 milk samples were obtained at unspecified times and nicardipine was undetectable (less than 5 mcg/L) in 82% of the samples.
Four women who received 1 to 6.5 mg/hour of nicardipine had 6 milk samples with detectable nicardipine levels (range 5.1 to 18.5 mcg/L). The highest concentration of 18.5 mcg/L was found in a woman who received 5.5 mg/hour of nicardipine. The estimated maximum dose in a breastfed infant was less than 0.3 mcg daily or 0.015% to 0.004% of the therapeutic dose in a 1 kg infant.
Mechanism of action
12.1 Mechanism of Action Nicardipine inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. The effects of nicardipine are more selective to vascular smooth muscle than cardiac muscle. In animal models, nicardipine produced relaxation of coronary vascular smooth muscle at drug levels which cause little or no negative inotropic effect.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Hemodynamics Nicardipine produces significant decreases in systemic vascular resistance. In a study of intra-arterially administered nicardipine, the degree of vasodilation and the resultant decrease in blood pressure were more prominent in hypertensive patients than in normotensive volunteers. Administration of nicardipine to normotensive volunteers at dosages of 0.25 mg/hr to 3 mg/hr for eight hours produced changes of less than 5 mmHg in systolic blood pressure and less than 3 mmHg in diastolic blood pressure.
An increase in heart rate is a normal response to vasodilation and decrease in blood pressure; in some patients these increases in heart rate may be pronounced. In placebo-controlled trials, the mean increases in heart rate were 7 ± 1 bpm in postoperative patients and 8 ± 1 bpm in patients with severe hypertension at the end of the maintenance period.
Hemodynamic studies following intravenous dosing in patients with coronary artery disease and normal or moderately abnormal left ventricular function have shown significant increases in ejection fraction and cardiac output with no significant change, or a small decrease, in left ventricular end-diastolic pressure (LVEDP). There is evidence that nicardipine increases blood flow.
Coronary dilatation induced by nicardipine improves perfusion and aerobic metabolism in areas with chronic ischemia, resulting in reduced lactate production and augmented oxygen consumption. In patients with coronary artery disease, nicardipine, administered after beta-blockade, significantly improved systolic and diastolic left ventricular function.
In congestive heart failure patients with impaired left ventricular function, nicardipine increased cardiac output both at rest and during exercise. Decreases in left ventricular end-diastolic pressure were also observed. However, in some patients with severe left ventricular dysfunction, it may have a negative inotropic effect and could lead to worsened failure. “Coronary steal” has not been observed during treatment with nicardipine (Coronary steal is the detrimental redistribution of coronary blood flow in patients with coronary artery disease from underperfused areas toward better perfused areas.) Nicardipine has been shown to improve systolic shortening in both normal and hypokinetic segments of myocardial muscle.
Radionuclide angiography has confirmed that wall motion remained improved during increased oxygen demand. (Occasional patients have developed increased angina upon receiving nicardipine capsules. Whether this represents coronary steal in these patients, or is the result of increased heart rate and decreased diastolic pressure, is not clear.) In patients with coronary artery disease, nicardipine improves left ventricular diastolic distensibility during the early filling phase, probably due to a faster rate of myocardial relaxation in previously underperfused areas.
There is little or no effect on normal myocardium, suggesting the improvement is mainly by indirect mechanisms such as afterload reduction and reduced ischemia. Nicardipine has no negative effect on myocardial relaxation at therapeutic doses. The clinical benefits of these properties have not yet been demonstrated. Electrophysiologic Effects In general, no detrimental effects on the cardiac conduction system have been seen with nicardipine.
During acute electrophysiologic studies, it increased heart rate and prolonged the corrected QT interval to a minor degree. It did not affect sinus node recovery or SA conduction times. The PA, AH, and HV intervals* or the functional and effective refractory periods of the atrium were not prolonged. The relative and effective refractory periods of the His-Purkinje system were slightly shortened. *PA = conduction time from high to low right atrium; AH = conduction time from low right atrium to His bundle deflection, or AV nodal conduction time; HV = conduction time through the His bundle and the bundle branch-Purkinje system.
Hepatic Function Because nicardipine is extensively metabolized by the liver, plasma concentrations are influenced by changes in hepatic function. In a clinical study with nicardipine capsules in patients with severe liver disease, plasma concentrations were elevated and the half-life was prolonged [see Warnings and Precautions (5.5)].
Similar results were obtained in patients with hepatic disease when nicardipine hydrochloride was administered for 24 hours at 0.6 mg/hr. Renal Function When nicardipine was given to mild-to-moderate hypertensive patients with moderate degrees of renal impairment, significant reduction in glomerular filtration rate (GFR) and effective renal plasma flow (RPF) were observed.
No significant differences in liver blood flow were observed in these patients. A significantly lower systemic clearance and higher area under the curve (AUC) were observed. When nicardipine capsules (20 or 30 mg TID) were given to hypertensive patients with impaired renal function, mean plasma concentrations, AUC, and C max were approximately two-fold higher than in healthy controls.
There was a transient increase in electrolyte excretion, including sodium [see Warnings and Precautions (5.6)]. Acute bolus administration of nicardipine hydrochloride injection (2.5 mg) in healthy volunteers decreased mean arterial pressure and renal vascular resistance; glomerular filtration rate (GFR), renal plasma flow (RPF), and the filtration fraction were unchanged.
In healthy patients undergoing abdominal surgery, nicardipine hydrochloride injection (10 mg over 20 minutes) increased GFR with no change in RPF when compared with placebo. In hypertensive type ll diabetic patients with nephropathy, nicardipine capsules (20 mg TID) did not change RPF and GFR, but reduced renal vascular resistance.
Pulmonary Function In two well-controlled studies of patients with obstructive airway disease treated with nicardipine capsules, no evidence of increased bronchospasm was seen. In one of the studies, nicardipine capsules improved forced expiratory volume 1 second (FEV 1) and forced vital capacity (FVC) in comparison with metoprolol.
Adverse reactions reported in a limited number of patients with asthma, reactive airway disease, or obstructive airway disease were similar to reactions in other patients treated with nicardipine capsules.
Pharmacokinetics
Following infusion, nicardipine plasma concentrations decline triexponentially, with a rapid early distribution phase (α-half-life of 3 minutes), an intermediate phase (ß-half-life of 45 minutes), and a slow terminal phase (ƴ-half-life of 14 hours) that can only be detected after long-term infusions.
Metabolism and Excretion Nicardipine has been shown to be rapidly and extensively metabolized by the hepatic cytochrome P450 enzymes, CYP2C8, 2D6, and 3A4.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Distribution A rapid dose-related increase in nicardipine plasma concentrations is seen during the first two hours after the start of an infusion of nicardipine. Plasma concentrations increase at a much slower rate after the first few hours, and approach steady state at 24 to 48 hours. The steady-state pharmacokinetics of nicardipine are similar in elderly hypertensive patients (greater than 65 years) and young healthy adults.
On termination of the infusion, nicardipine concentrations decrease rapidly, with at least a 50% decrease during the first two hours post-infusion. The effects of nicardipine on blood pressure significantly correlate with plasma concentrations. Nicardipine is highly protein bound (greater than 95%) in human plasma over a wide concentration range.
Following infusion, nicardipine plasma concentrations decline triexponentially, with a rapid early distribution phase (α-half-life of 3 minutes), an intermediate phase (ß-half-life of 45 minutes), and a slow terminal phase (ƴ-half-life of 14 hours) that can only be detected after long-term infusions. Total plasma clearance (Cl) is 0.4 L/hr•kg, and the apparent volume of distribution (Vd) using a non-compartment model is 8.3 L/kg.
The pharmacokinetics of nicardipine is linear over the dosage range of 0.5 mg/hr to 40 mg/hr. Metabolism and Excretion Nicardipine has been shown to be rapidly and extensively metabolized by the hepatic cytochrome P450 enzymes, CYP2C8, 2D6, and 3A4. Nicardipine does not induce or inhibit its own metabolism; however, nicardipine has been shown to inhibit certain cytochrome P450 enzymes (including CYP3A4, CYP2D6, CYP2C8, and CYP2C19).
Inhibition of these enzymes may result in increased plasma levels of certain drugs, including cyclosporine and tacrolimus [see Drug Interactions (7.5, 7.6)]. The altered pharmacokinetics may necessitate dosage adjustment of the affected drug or discontinuation of treatment. After coadministration of a radioactive intravenous dose of nicardipine with an oral 30 mg dose given every 8 hours, 49% of the radioactivity was recovered in the urine and 43% in the feces within 96 hours.
None of the dose was recovered as unchanged nicardipine.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Nicardipine 1 mg/mL, 10 mL Ampule | ₱106.23–₱420.00Reference ₱190.12 | per ampule | DPRI procurement range |
| Nicardipine 1 mg/mL, 2 mL Ampule | ₱61.22–₱419.85Reference ₱80.50 | per ampule | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Nicardipine (as hydrochloride) |
| PNF listing | Inj.: 1 mg/mL, 2 mL and 10 mL ampul (IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Nicardipine Hydrochloride · Hikma Pharmaceuticals USA Inc. [US FDA-approved label, version 6, July 21, 2021]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55bd6dcc-1f12-4378-8e9e-1ceed26818f5
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .